Skip to main content
. 2019 Feb 4;3(4):525–541. doi: 10.1002/hep4.1311

Figure 3.

Figure 3

Single and combination use of anti‐PD‐1 and tMNV‐directed therapy targeting β‐catenin for experimental HCC. (A) Experimental schematic. HDI with MET/β‐catenin as performed to induce HCC. Three weeks after HDI, mice were randomized into one of four 2‐week treatment groups (control, anti‐PD‐1, tMNVs [siRNA to β‐catenin], or anti‐PD‐1 with tMNVs [siRNA to β‐catenin]). Blood samples were collected every 3 weeks to monitor tumor growth. All animals were euthanized at 12 weeks. (B,C) Representative livers from each group are shown to illustrate the (B) gross appearance and (C) histologic features of liver within each group with H&E and immunohistochemistry for β‐catenin and Ki67 and PD‐L1 (magnification ×20). Abbreviation: HDI, Hydrodynamic injection.